CORRELATION OF LOW HISTIDINE-RICH GLYCOPROTEIN PLASMA-LEVELS WITH THE OCCURRENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION

被引:0
|
作者
MAUZKORHOLZ, C [1 ]
KORHOLZ, D [1 ]
BURDACH, S [1 ]
机构
[1] UNIV DUSSELDORF,MED CTR,DEPT PEDIAT HEMATOL & ONCOL,D-40225 DUSSELDORF,GERMANY
来源
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Histidine-rich glycoprotein (HRGP) is a potent inhibitor of T cell activation and production of cytokines such as (gamma-IFN). gamma-IFN released by activated T cells is increased during a short-term period at the onset of GvHD after allogeneic bone marrow transplantation. Therefore we investigated HRGP plasma levels in patients after BMT. Blood was collected from 20 children before and up to 6 weeks after BMT. In patients without GvHD, HRGP plasma levels decreased during the first week after BMT to 237 +/- 60 mu g/ml, compared with 302 +/- 104 mu g/ml before transplantation. However, no significant changes in mean HRGP plasma levels were observed during the following 5 weeks of the posttransplantation period. Acute GvHD occurred in 10 of 20 patients between the second and third week after BMT. HRGP levels (mean +/- SEM) in patients with GvHD dropped during the first week to 158 +/- 32 mu g/ml, compared with pretransplant levels of 240 +/- 48 mu g/ml). In contrast to results in patients without GvHD, a second and significant decrease was obtained between the second and third week after BMT in patients with GvHD (161 +/- 35 mu g/ml vs 84 +/- 13 mu g/ml; p < 0.01). In the third week after BMT, HRGP levels were significantly lower in patients with GvHD as compared with patients without GVHD (166 +/- 29 mu g/ml; p < 0.01). The decrease in HRGP in the second and third posttransplantation week was not a result of steroid treatment. Although HRGP down-regulates gamma-IFN production in vitro, no increase in gamma-IFN levels was observed in our patients, probably because plasma levels were measured only on a weekly basis. In conclusion, a drop in HRGP plasma levels between the second and third week after BMT might be of diagnostic value for the occurrence of acute GvHD. However, the role of HRGP in the cytokine dysregulation leading to the clinical manifestation of GvHD remains to be determined.
引用
收藏
页码:144 / 150
页数:7
相关论文
共 50 条
  • [21] CORRELATION BETWEEN DONOR CYTOMEGALOVIRUS IMMUNITY AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    JACOBSEN, N
    ANDERSEN, HK
    SKINHOJ, P
    RYDER, LP
    PLATZ, P
    JERNE, D
    FABER, V
    SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 1986, 36 (05): : 499 - 506
  • [22] Graft-Versus-Host Disease of the CNS After Allogeneic Bone Marrow Transplantation
    Saad, Ali G.
    Alyea, Edwin P., III
    Wen, Patrick Y.
    DeGirolami, Umberto
    Kesari, Santosh
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : E147 - E149
  • [23] ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC MARROW TRANSPLANTATION
    PARKER, N
    COHEN, T
    NURSING CLINICS OF NORTH AMERICA, 1983, 18 (03) : 569 - 577
  • [24] DIAGNOSIS AND GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION BY SIGMOIDOSCOPY
    KREISEL, W
    HERBST, EW
    SCHWIND, B
    OCHS, A
    OLSCHEWSKI, M
    KOCHLING, G
    FAUSER, AA
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (08) : 723 - 729
  • [25] CHEMOTHERAPY-INDUCED ACRAL ERYTHEMA AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    REYNAERT, H
    DECONINCK, A
    NEVEN, AM
    VANCAMP, B
    SCHOTS, R
    BONE MARROW TRANSPLANTATION, 1992, 10 (02) : 185 - 187
  • [26] FK-506 REVERSES ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION IN RATS
    MARKUS, PM
    CAI, X
    MING, W
    DEMETRIS, AJ
    FUNG, JJ
    STARZL, TE
    SURGERY, 1991, 110 (02) : 357 - 364
  • [27] COMBINATION OF CYCLOSPORINE AND METHOTREXATE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA
    MRSIC, M
    LABAR, B
    BOGDANIC, V
    NEMET, D
    PAVLETIC, Z
    PLAVSIC, F
    DOBRIC, I
    MARUSIC, M
    FRANCETIC, I
    KASTELAN, A
    KALENIC, S
    VRTAR, M
    MARKULINGRGIC, L
    AURER, I
    BONE MARROW TRANSPLANTATION, 1990, 6 (02) : 137 - 141
  • [28] ALLOGENEIC SKIN TRANSPLANTATION IN CHRONIC GRAFT-VERSUS-HOST DISEASE FOLLOWING BONE-MARROW TRANSPLANTATION
    BAUMEISTER, RGH
    RIEL, KA
    KOLB, HJ
    CHIRURG, 1990, 61 (06): : 438 - 440
  • [29] THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
    MCCARTHY, DM
    KANFER, EJ
    BARRETT, AJ
    BIOMEDICINE & PHARMACOTHERAPY, 1989, 43 (09) : 693 - 697
  • [30] ANTIPHOSPHOLIPID SYNDROME COMPLICATING CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    SOHNGEN, D
    HEYLL, A
    MECKENSTOCK, G
    AUL, C
    WOLF, HH
    SCHNEIDER, W
    SPECKER, C
    WITHOLD, W
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (02) : 143 - 144